Audit: QRS - Losartan for Health & Longevity

Audit conducted on 16/10/2026 03:08 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	84
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All QRS statements trace to ER text (e.g., at-a-glance to Conclusion/Motivation; protocol cells to Therapeutic Protocol bullets; interactions to Key Interactions bullets).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious phrasing retained: ‘(theoretical)’ tags, ‘not studied’, ‘net blood pressure effect untested’, ‘clinical impact likely small’.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Only atenolol (named in ER for the same stroke finding) appears; no PMIDs, NCTs, or brand names.
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Jargon glossed in plain language (fluid loss, kidney filtering capacity, irregular heart rhythm, main artery’s base).
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance notes the longevity case rests mainly on animal studies, distinguishing it from established blood pressure and kidney benefits.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Lede uses ‘oral prescription blood pressure medication’.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template spans present, with marker_# and qualitative_item_# expanded to 7 and 6 rows.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website spans, footer, and template comments unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section used by the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (‘Hypertension (product label)’, ‘Single versus split dose’, ‘Time of day’) and interaction labels match ER bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Sections are condensed: 20 ER interaction bullets merged to 13 short items without rationale; tiers reduced to headline terms.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration is quoted, as its value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.10.15 matches QRS.md version.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-1016 → 10/16/2026.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens ‘Losartan, an inexpensive oral prescription blood pressure medication, blocks a hormone…’.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.3	[at_a_glance] is no longer than 70 words	🟢	70 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All 7 ER ‘Populations who should avoid’ items plus ER ‘Avoid’/’Contraindicated’ items (ACE inhibitors, aliskiren).
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Qualifiers kept: boxed warning, GFR thresholds, ‘not studied’, ‘not recommended’, breastfeeding exception.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section is populated, as the ER identifies populations to avoid.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ER interactions covered; ACE inhibitors and aliskiren excluded as they appear under Contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists preserved (trimmed glosses only).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section is populated, as the ER identifies interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Labeled hypertension dosing, split dosing, and time of day.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides more than three actionable aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Blood pressure, kidney protection, cardiovascular outcomes from ER Practical Considerations.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Blood pressure and kidney (High tier) precede cardiovascular outcomes (Medium tier).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides three time-to-effect aspects.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	Only plain-language glosses of technical terms remain; no effect sizes, sample notes, or example studies.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	Only a plain-language gloss of angioedema remains; no frequencies or severity grades.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 7 ER table biomarkers listed.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 6 ER qualitative markers listed.

Issues 16/10/2026 03:08

Pass rate 100.00%. No issues found.

Issues 16/10/2026 03:04

1. 1.3 — Pediatric GFR restriction broadened: Contraindications line 548 reads “Children under 6 years, or with kidney filtering capacity (GFR) below 30 mL/min/1.73 m²”, dropping the ER’s second “children” and allowing a reading that covers anyone with GFR below 30.
2. 2.7 — Clinical jargon in protocol: Protocol action_1_sub (line 450) uses “volume depletion” without a plain-language equivalent, although the ER also uses “fluid loss” for the concept.

Fixes 16/10/2026 03:04

1. 1.3 — Pediatric GFR restriction clarified: Changed “Children under 6 years, or with kidney filtering capacity (GFR) below 30 mL/min/1.73 m²” to “Children under 6 years, or children with kidney filtering capacity (GFR) below 30 mL/min/1.73 m²”, matching the ER.
2. 2.7 — Plain language for volume depletion: Changed action_1_sub from “Start 25 mg with possible volume depletion or liver impairment” to “Start 25 mg with possible fluid loss (volume depletion) or liver impairment”.

Issues 16/10/2026 03:01

1. 1.1 — Unsupported fainting for supplements: In Key Interactions (line 566), blood pressure-lowering supplements are merged with PDE5 inhibitors, alpha-blockers and alcohol under “dizziness or fainting”, but the ER supports only “additive lowering may cause dizziness” for supplements.
2. 4.5 — Interactions gate not condensed: The Key Interactions gate (lines 557-568) has two items of roughly 250 characters each with full parenthetical glosses, so the sheet exceeds the one-page A4 budget.

Fixes 16/10/2026 03:01

1. 1.1 — Supplements fainting claim removed: Split blood pressure-lowering supplements out of the PDE5/alpha-blocker/alcohol item into their own Key Interactions entry with “Monitor (theoretical), dizziness”, matching the ER.
2. 4.5 — Interactions gate condensed: Trimmed parenthetical glosses in Key Interactions (“potassium chloride ‘lite’ salts” to “potassium chloride”; “erectile dysfunction drugs: sildenafil, tadalafil” to “sildenafil, tadalafil”) to shorten the two longest items.

Issues 16/10/2026 02:58

1. 9.5 — Salt substitute examples dropped: At QRS line 557, “potassium-containing salt substitutes” omits the ER’s parenthetical example “(potassium chloride “lite” salts)” (ER line 352), which 9.5 requires to be preserved.
2. 13.3 / 13.4 — Nitrosamine parenthetical not stripped: At QRS line 587, the Low-tier risk “nitrosamine impurity exposure (potential carcinogen in some recalled generic lots)” keeps an explanatory parenthetical that should be stripped.

Fixes 16/10/2026 02:58

1. 9.5 — Salt substitute examples restored: Added the ER’s parenthetical “(potassium chloride “lite” salts)” after “potassium-containing salt substitutes” in the first Key Interactions item.
2. 13.3 / 13.4 — Nitrosamine parenthetical stripped: Changed the Low-tier risk from “nitrosamine impurity exposure (potential carcinogen in some recalled generic lots)” to “nitrosamine impurity exposure”.

Issues 16/10/2026 02:54

1. 2.7 — Unexplained specialist terms: “atrial fibrillation” and “aortic root” (benefits_medium, line 525), “mitochondrial function” (benefits_speculative, line 531), and “angioedema” and “nitrosamine impurity exposure” (risks_low, line 593) appear without the plain-language glosses the ER provides.
2. 4.5 — Exceeds one A4 page: caution_items (lines 557-574) lists 18 separate interactions with long verbatim parenthetical glosses; items sharing the same effect were not condensed, pushing the sheet well beyond one A4 page.

Fixes 16/10/2026 02:54

1. 2.7 — Plain-language glosses added: Added short ER-derived glosses for “atrial fibrillation (irregular heart rhythm)”, “aortic root (main artery’s base)”, “mitochondrial (cellular energy) function”, “angioedema (sudden deep swelling of face or throat)” and “nitrosamine impurity exposure (potential carcinogen in some recalled generic lots)”.
2. 4.5 — Interactions condensed for page: Merged caution_items with identical effects (potassium-raising agents; rifampin and milk thistle; vessel-relaxing drugs, alcohol and blood pressure-lowering supplements) and trimmed long parenthetical glosses, reducing 18 items to 12 while keeping all example drug lists; also shortened the children contraindication wording.

Issues 16/10/2026 02:50

1. 2.7 — Jargon left unexplained: Key Interactions lines 563-564 drop the ER glosses, leaving “PDE5 inhibitors”, “alpha-blockers” and “COX-2 inhibitors” unexplained; Monitoring marker_3_name (line 637) leaves “eGFR” unexplained.
2. 4.2 / 4.3 — Interaction labels abbreviated: Bold labels at lines 563 and 564 shorten the ER labels (ER lines 347, 351), omitting “erectile dysfunction drugs that widen vessels:”, “vessel-relaxing drugs:” and “selective anti-inflammatories:”.

Fixes 16/10/2026 02:50

1. 2.7 / 4.2 / 4.3 — Interaction labels restored verbatim: Restored the ER bold labels for PDE5 inhibitors/alpha-blockers (“erectile dysfunction drugs that widen vessels:”, “vessel-relaxing drugs:”) and NSAIDs (“selective anti-inflammatories:”), reinstating the plain-language glosses.
2. 2.7 — eGFR explained: Changed marker_3_name from “Serum creatinine and eGFR” to “Serum creatinine and eGFR (kidneys’ filtering capacity)”, using the ER’s own gloss.

Issues 16/10/2026 02:47

1. 2.7 — Unexplained GFR acronym: The Contraindications items at lines 543 and 548 use “GFR” without a plain-language explanation, although the ER expands it as glomerular filtration rate, the kidneys’ filtering capacity.

Fixes 16/10/2026 02:47

1. 2.7 — Explained GFR acronym: In both Contraindications items, changed “GFR below …” to “kidney filtering capacity (GFR) below …”, matching the ER’s definition.

Issues 16/10/2026 02:43

1. 2.7 — Unexplained jargon in gates: “hyperkalemia” appears unexplained in Key Interactions (lines 557, 561, 565, 567) and “hypotension” at line 574, before the Risks card; “Severe hepatic impairment” (line 547) and “usual antihypertensives” (line 472) use technical terms where plain ER equivalents exist.
2. 2.8 / 4.5 — Not condensed to one page: Redundant text (action_1_sub repeats the 100 mg maximum, lines 447/450; long creatinine target, line 640) and an 18-item interaction list push the sheet well beyond one A4 page.
3. 13.4 — Parentheticals kept in risks: “Hyperkalemia (high blood potassium)” (line 587) and “lower hemoglobin (anemia)” (line 590) retain parenthetical content that should be stripped.

Fixes 16/10/2026 02:43

1. 2.7 — Plain-language gate wording: Replaced “hyperkalemia” with “high blood potassium” in four Key Interactions items, “hypotension” with “low blood pressure” in the heat/fluid-loss item, “Severe hepatic impairment” with “Severe liver impairment”, and “usual antihypertensives” with “usual blood pressure medications” in action_3_sub.
2. 2.8 / 4.5 — Redundant text condensed: Removed the repeated “Maximum 100 mg once daily” from action_1_sub and trimmed “track change from own baseline” from the creatinine/eGFR target, keeping “no established target”.
3. 13.4 — Risk parentheticals stripped: Changed “Hyperkalemia (high blood potassium)” to “High blood potassium” and “lower hemoglobin (anemia)” to “lower hemoglobin”.

Issues 16/10/2026 02:39

1. 4.2 / 4.3 — Invented protocol cell labels: action_1_label “Starting dose” and action_2_label “Titration” (QRS lines 444, 455) are not ER bold labels; the source bullet is “Hypertension (product label):” (ER line 400).
2. 8.4 — Attribution in pregnancy item: The pregnancy contraindication (QRS line 542) retains “label directs stopping as soon as detected”, an attribution/elaboration beyond the key fact.

Fixes 16/10/2026 02:39

1. 4.2 / 4.3 — Protocol labels use ER labels: Replaced invented labels “Starting dose” and “Titration” with the ER bold labels “Hypertension (product label)” (start 50 mg, maximum 100 mg, 25 mg start when volume-depleted or liver-impaired) and “Single versus split dose” (50 mg twice daily); the “Time of day” cell now carries only its own ER content, including the “usual antihypertensives” qualifier.
2. 8.4 — Pregnancy item trimmed: Changed “Pregnancy at any stage (boxed warning; label directs stopping as soon as detected)” to “Pregnancy at any stage (boxed warning)”.

Issues 16/10/2026 02:36

1. 1.2 — Cautious target wording dropped: marker_3_target (line 640) omits “about” before the creatinine ranges and “No established target” for eGFR, both present in the ER Monitoring table (ER line 465).
2. 2.6 / 2.9 — Imperative addresses reader: The pregnancy contraindication (line 542) reads “(stop as soon as detected)”, an instruction to the reader rather than a statement of what the label directs.
3. 8.5 — Severity qualifiers dropped: The pregnancy item (line 542) omits “boxed warning” and the children item (line 548) omits “not recommended” from the ER bullets (ER lines 371, 376).
4. 4.2 / 9.5 — Salt substitute qualifier dropped: The Key Interactions label “Potassium-containing salt substitutes” (line 565) drops the ER parenthetical “(potassium chloride “lite” salts)” entirely (ER line 352).

Fixes 16/10/2026 02:36

1. 1.2 — Cautious target wording restored: Changed marker_3_target to “Creatinine about 0.7–1.3 mg/dL (men), 0.6–1.1 mg/dL (women); eGFR: no established target, track change from own baseline”.
2. 2.6 / 2.9 — Imperative replaced: Changed the pregnancy item’s “(stop as soon as detected)” to “label directs stopping as soon as detected”.
3. 8.5 — Severity qualifiers restored: Added “boxed warning” to the pregnancy item and “(not recommended)” to the children item.
4. 4.2 / 9.5 — Salt substitute qualifier restored: Changed the label to “Potassium-containing salt substitutes (potassium chloride “lite” salts):”.